BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Amrecibart readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Amrecibart\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07175428-11312@assetmemo.bio
DTSTAMP:20261121T005643Z
DTSTART;VALUE=DATE:20270209
DTEND;VALUE=DATE:20270210
SUMMARY:Amrecibart: Phase 2 readout est. (NCT07175428)
DESCRIPTION:Amrecibart\, phase 2.\nStudy: Safety in Adult Participants With
  Atrial Fibrillation Who Are Treated With Anticoagulation\nEstimated prima
 ry completion: 9 February 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/amrecibart#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07175428
URL:https://assetmemo.bio/drug/amrecibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07759167-11312@assetmemo.bio
DTSTAMP:20261121T005643Z
DTSTART;VALUE=DATE:20270402
DTEND;VALUE=DATE:20270403
SUMMARY:Amrecibart: Phase 1 readout est. (NCT07759167)
DESCRIPTION:Amrecibart\, phase 1.\nStudy: Study of 3 Monoclonal Antibodies 
 (REGN9933\, REGN7508\, and REGN9533) in Adult Participants With End-Stage 
 Kidney Disease on Hemodialysis\nEstimated primary completion: 2 April 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/amrecibart#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07759167
URL:https://assetmemo.bio/drug/amrecibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07430956-11312@assetmemo.bio
DTSTAMP:20261121T005643Z
DTSTART;VALUE=DATE:20290328
DTEND;VALUE=DATE:20290329
SUMMARY:Amrecibart: Phase 3 readout est. (NCT07430956)
DESCRIPTION:Amrecibart\, phase 3.\nStudy: Stroke and Systemic Embolism Prev
 ention in Adult Participants With Atrial Fibrillation for Whom Oral Antico
 agulation is Unsuitable\nEstimated primary completion: 28 March 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/amrecibart#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07430956
URL:https://assetmemo.bio/drug/amrecibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07697599-11312@assetmemo.bio
DTSTAMP:20261121T005643Z
DTSTART;VALUE=DATE:20290625
DTEND;VALUE=DATE:20290626
SUMMARY:Amrecibart: Phase 3 readout est. (NCT07697599)
DESCRIPTION:Amrecibart\, phase 3.\nStudy: Venous Thromboembolism (VTE) Prop
 hylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants Wi
 th a Peripherally Inserted Central Catheter (PICC)\nEstimated primary comp
 letion: 25 June 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /amrecibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07697599
URL:https://assetmemo.bio/drug/amrecibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318610-11312@assetmemo.bio
DTSTAMP:20261121T005643Z
DTSTART;VALUE=DATE:20290818
DTEND;VALUE=DATE:20290819
SUMMARY:Amrecibart: Phase 3 readout est. (NCT07318610)
DESCRIPTION:Amrecibart\, phase 3.\nStudy: Reducing Adverse Vascular Outcome
 s With Factor XI Inhibition in Adult Participants With Peripheral Artery D
 isease\nEstimated primary completion: 18 August 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/amrecibart#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07318610
URL:https://assetmemo.bio/drug/amrecibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
